The Link between Type 2 Diabetes and Neurodegeneration: Roles for Amyloid-β, Amylin, and Tau Proteins

Journal of Alzheimer's Disease

Volumn 59, Issue 2, 2017, Pages 421-432

  Bharadwaj, Prashant ^a,b   Wijesekara, Nadeeja ^c   Liyanapathirana, Milindu ^a   Newsholme, Philip ^a   Ittner, Lars ^d   Fraser, Paul ^c   Verdile, Giuseppe ^a,b,e  

^a CURTIN UNIVERSITY   (Australia)

^b EDITH COWAN UNIVERSITY   (Australia)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Alzheimer's disease; amylin; amyloid protein; insulin; tau; type 2 diabetes

Indexed keywords

AMYLIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; TAU PROTEIN;

BRAIN ATROPHY; CENTRAL NERVOUS SYSTEM; CYTOTOXICITY; DISEASE ASSOCIATION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NERVE CELL DEGENERATION; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PHENOTYPE; PRIORITY JOURNAL; REVIEW; ANIMAL; BRAIN; DEGENERATIVE DISEASE; GENETICS; METABOLISM; PATHOLOGY;

AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; DIABETES MELLITUS, TYPE 2; HUMANS; ISLET AMYLOID POLYPEPTIDE; NEURODEGENERATIVE DISEASES; TAU PROTEINS;

EID: 85019844204     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-161192     Document Type: Review

References (126)

1. Zhang Y, Zhou B, Zhang F, Wu J, Hu Y, Liu Y, Zhai Q (2012) Amyloid-β induces hepatic insulin resistance by activating JAK2/STAT3/SOCS-1 signaling pathway. Diabetes 61, 1434-1443.
2. Mody N, Agouni A, McIlroy GD, Platt B, Delibegovic M (2011) Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1 (A246E) mouse model of Alzheimer's disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein. Diabetologia 54, 2143-2151.
3. Vandal M, White PJ, Chevrier G, Tremblay C, St-Amour I, Planel E, Marette A, Calon F (2015) Age-dependent impairment of glucose tolerance in the 3xTg-AD mouse model of Alzheimer's disease. FASEB J 29, 4273-4284.
4. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18, 902-904.
5. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R (2010) Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 107, 7036-7041.
6. Hiltunen M, Khandelwal VK, Yaluri N, Tiilikainen T, Tusa M, Koivisto H, Krzisch M, Vepsäläinen S, Mäkinen P, Kemppainen S, Miettinen P, Haapasalo A, Soininen H, Laakso M, Tanila H (2012) Contribution of genetic and dietary insulin resistance to Alzheimer phenotype in APP/PS1 transgenic mice. J Cell Mol Med 16, 1206-1222.
7. Jiménez-Palomares M, Ramos-Rodríguez JJ, López-Acosta JF, Pacheco-Herrero M, Lechuga-Sancho AM, Perdomo G, García-Alloza M, Cózar-Castellano I (2012) Increased Aβ production prompts the onset of glucose intolerance and insulin resistance. Am J Physiol Endocrinol Metab 302, E1373-E1380.
8. Infante-Garcia C, Ramos-Rodriguez JJ, Galindo-Gonzalez L, Garcia-Alloza M (2016) Long-term central pathology and cognitive impairment are exacerbated in a mixed model of Alzheimer's disease and type 2 diabetes. Psychoneuroendocrinology 65, 15-25.
9. Niedowicz DM, Reeves VL, Platt TL, Kohler K, Beckett TL, Powell DK, Lee TL, Sexton TR, Song ES, Brewer LD, Latimer CS, Kraner SD, Larson KL, Ozcan S, Norris CM, Hersh LB, Porter NM, Wilcock DM, Murphy MP (2014) Obesity and diabetes cause cognitive dysfunction in the absence of accelerated β-amyloid deposition in a novel murine model of mixed or vascular dementia. Acta Neuropathol Commun 2, 64.
10. Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8, 595-608.
11. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL, Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group (2013) Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 12, 357-367.
12. Ittner LM, Götz J (2011) Amyloid-β and tau-a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12, 65-72.
13. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142, 387-397.
14. Clark A, Saad MF, Nezzer T, Uren C, Knowler WC, Bennett PH, Turner RC (1990) Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 33, 285-289.
15. Westermark P (1972) Quantitative studies on amyloid in the islets of Langerhans. Ups J Med Sci 77, 91-94.
16. Oskarsson ME, Paulsson JF, Schultz SW, Ingelsson M, Westermark P, Westermark GT (2015) In vivo seeding and cross-seeding of localized amyloidosis: A molecular link between type 2 diabetes and Alzheimer disease. Am J Pathol 185, 834-846.
17. Kahn SE, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky GJ Jr, Porte D Jr (1990) Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes 39, 634-638.
18. Lutz TA (2010) Roles of amylin in satiation, adiposity and brain development. Forum Nutr 63, 64-74.
19. Lutz TA (2012) Control of energy homeostasis by amylin. Cell Mol Life Sci 69, 1947-1965.
20. Boyle CN, Rossier MM, Lutz TA (2011) Influence of high-fat feeding, diet-induced obesity, and hyperamylinemia on the sensitivity to acute amylin. Physiol Behav 104, 20-28.
21. Osaka T, Tsukamoto A, Koyama Y, Inoue S (2008) Central and peripheral administration of amylin induces energy expenditure in anesthetized rats. Peptides 29, 1028-1035.
22. Wielinga PY, Löwenstein C, Muff S, Munz M, Woods SC, Lutz TA (2010) Central amylin acts as an adiposity signal to control body weight and energy expenditure. Physiol Behav 101, 45-52.
23. Sexton PM, Paxinos G, Kenney MA, Wookey PJ, Beaumont K (1994) In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 62, 553-567.
24. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102-110.
25. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC (1999) The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48, 491-498.
26. Jackson K, Barisone GA, Diaz E, Jin LW, DeCarli C, Despa F (2013) Amylin deposition in the brain: A second amyloid in Alzheimer disease? Ann Neurol 74, 517-526.
27. Fawver JN, Ghiwot Y, Koola C, Carrera W, Rodriguez-Rivera J, Hernandez C, Dineley KT, Kong Y, Li J, Jhamandas J, Perry G, Murray IV (2014) Islet amyloid polypeptide (IAPP): A second amyloid in Alzheimer's disease. Curr Alzheimer Res 11, 928-940.
28. Oddo S, Caccamo A, Shepherd JD, MurphyMP, Golde TE, Kayed R, Metherate R, MattsonMP, AkbariY, LaFerlaFM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Aβ and synaptic dysfunction. Neuron 39, 409-421.
29. Mehla J, Chauhan BC, Chauhan NB (2014) Experimental induction of type 2 diabetes in aging-accelerated mice triggered Alzheimer-like pathology and memory deficits. J Alzheimers Dis 39, 145-162.
30. Knight EM, Martins IV, Gümüsgöz S, Allan SM, Lawrence CB (2014) High-fat diet-induced memory impairment in triple-transgenic Alzheimer's disease (3xTgAD) mice is independent of changes in amyloid and tau pathology. Neurobiol Aging 35, 1821-1832.
31. Wang Y, Wu L, Li J, Fang D, Zhong C, Chen JX, Yan SS (2015) Synergistic exacerbation of mitochondrial and synaptic dysfunction and resultant learning and memory deficit in a mouse model of diabetic Alzheimer's disease. J Alzheimers Dis 43, 451-463.
32. Ferreira ST, Clarke JR, Bomfim TR, De Felice FG (2014) Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. Alzheimers Dement 10, S76-S83.
33. Verdile G, Keane KN, Cruzat VF, Medic S, Sabale M, Rowles J, Wijesekara N, Martins RN, Fraser PE, Newsholme P (2015) Inflammation and oxidative stress: The molecular connectivity between insulin resistance, obesity, and Alzheimer's disease. Mediators Inflamm 2015, 105828.
34. Verdile G, Fuller SJ, Martins RN (2015) The role of type 2 diabetes in neurodegeneration. Neurobiol Dis 84, 22-38.
35. Porte D Jr, Baskin DG, Schwartz MW (2005) Insulin signaling in the central nervous system: A critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 54, 1264-1276.
36. De Felice FG, Benedict C (2015) A key role of insulin receptors in memory. Diabetes 64, 3653-3655.
37. Frölich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A, Türk A, Hoyer S, Zochling R, Boissl KW, Jellinger K, Riederer P (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm (Vienna) 105, 423-438.
38. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: Link to brain reductions in acetylcholine. J Alzheimers Dis 8, 247-268.
39. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7, 63-80.
40. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122, 1316-1338.
41. Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31, 224-243.
42. Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vinters HV, Frautschy SA, Cole GM (2009) Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: Suppression by omega-3 fatty acids and curcumin. J Neurosci 29, 9078-9089.
43. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: Relationship to severity of dementia and apolipoprotein E genotype. Neurology 50, 164-168.
44. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH 2nd, Craft S (2008) Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 13, 323-331.
45. Krishnaswamy S, Verdile G, Groth D, Kanyenda L, Martins RN (2009) The structure and function of Alzheimer's gamma secretase enzyme complex. Crit Rev Clin Lab Sci 46, 282-301.
46. Walsh DM, Teplow DB (2012) Alzheimer's disease and the amyloid β-protein. Prog Mol Biol Transl Sci 107, 101-124.
47. Son SM, Song H, Byun J, Park KS, Jang HC, Park YJ, Mook-Jung I (2012) Accumulation of autophagosomes contributes to enhanced amyloidogenic APP processing under insulin-resistant conditions. Autophagy 8, 1842-1844.
48. Vandal M, White PJ, Tremblay C, St-Amour I, Chevrier G, Emond V, Lefrançois D, Virgili J, Planel E, Giguere Y, Marette A, Calon F (2014) Insulin reverses the high-fat diet-induced increase in brain Aβ and improves memory in an animal model of Alzheimer disease. Diabetes 63, 4291-4301.
49. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087-1093.
50. Ling X, Martins RN, Racchi M, Craft S, Helmerhorst E (2002) Amyloid beta antagonizes insulin promoted secretion of the amyloid beta protein precursor. J Alzheimers Dis 4, 369-374.
51. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST, Klein WL (2009) Protection of synapses against Alzheimer'slinked toxins: Insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 106, 1971-1976.
52. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associatedAβ oligomers. J Clin Invest 122, 1339-1353.
53. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22, 246-260.
54. O'Neill C, Kiely AP, Coakley MF, Manning S, Long-Smith CM (2012) Insulin and IGF-1 signalling: Longevity, protein homoeostasis and Alzheimer's disease. Biochem Soc Trans 40, 721-727.
55. Doble BW, Woodgett JR (2003) GSK-3: Tricks of the trade for a multi-tasking kinase. J Cell Sci 116, 1175-1186.
56. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, Farhang-Fallah J, Dikkes P, Warot XM, Rio C, Corfas G, White MF (2003) Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 23, 7084-7092.
57. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, KondoT, Alber J, Galldiks N, Küstermann E, Arndt S, Jacobs AH, Krone W, Kahn CR, Bruning JC (2004) Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A 101, 3100-3105.
58. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787-795.
59. Reddy PH, Beal MF (2008) Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 14, 45-53.
60. Srodulski S, Sharma S, Bachstetter AB, Brelsfoard JM, Pascual C, Xie XS, Saatman KE, Van Eldik LJ, Despa F (2014) Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin. Mol Neurodegener 9, 30.
61. Nilsson MR, Driscoll M, Raleigh DP (2002) Low levels of asparagine deamidation can have a dramatic effect on aggregation of amyloidogenic peptides: Implications for the study of amyloid formation. Protein Sci 11, 342-349.
62. Akter R, Cao P, Noor H, Ridgway Z, Tu LH, Wang H, Wong AG, Zhang X, Abedini A, Schmidt AM, Raleigh DP (2016) Islet amyloid polypeptide: Structure, function, and pathophysiology. J Diabetes Res 2016, 2798269.
63. Guo JP, Arai T, Miklossy J, McGeer PL (2006) Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci U S A 103, 1953-1958.
64. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L (2001) beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 98, 12245-12250.
65. Lim YA, Ittner LM, Lim YL, Götz J (2008) Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures. FEBS Lett 582, 2188-2194.
66. Ono K, Takahashi R, Ikeda T, Mizuguchi M, Hamaguchi T, Yamada M (2014) Exogenous amyloidogenic proteins function as seeds in amyloid β-protein aggregation. Biochim Biophys Acta 1842, 646-653.
67. Yan LM, Velkova A, Tatarek-Nossol M, Andreetto E, Kapurniotu A (2007) IAPP mimic blocks Abeta cytotoxic self-assembly: Cross-suppression of amyloid toxicity of Abeta and IAPP suggests a molecular link between Alzheimer's disease and type II diabetes. Angew Chem Int Ed Engl 46, 1246-1252.
68. Andreetto E, Yan LM, Tatarek-Nossol M, Velkova A, Frank R, Kapurniotu A (2010) Identification of hot regions of the Abeta-IAPP interaction interface as high-affinity binding sites in both cross-and self-association. Angew Chem Int Ed Engl 49, 3081-3085.
69. Yan LM, Velkova A, Kapurniotu A (2014) Molecular characterization of the hetero-assembly of β-amyloid peptide with islet amyloid polypeptide. Curr Pharm Des 20, 1182-1191.
70. Butterfield DA, Drake J, Pocernich C, Castegna A (2001) Evidence of oxidative damage in Alzheimer's disease brain: Central role for amyloid beta-peptide. Trends Mol Med 7, 548-554.
71. Dyrks T, Dyrks E, Hartmann T, Masters CL, Beyreuther K (1992) Amyloidogenicity of βA4 and βA4-bearing amyloid protein precursor fragments by metal-catalysed oxidation. J Biol Chem 267, 18210-18217.
72. Palmblad M, Westlind-Danielsson A, Bergquist J (2002) Oxidation of methionine 35 attenuates formation of amyloid beta-peptide 1-40 oligomers. J Biol Chem 277, 19506-19510.
73. Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, Wu H (2004) ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304, 448-452.
74. Martins RN, Harper CG, Stokes GB, Masters CL (1986) Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J Neurochem 46, 1042-1045.
75. Yaar M, Zhai S, Pilch PF, Doyle SM, Eisenhauer PB, Fine RE, Gilchrest BA (1997) Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. J Clin Invest 100, 2333-2340.
76. Wei W, Norton DD, Wang X, Kusiak JW (2002) Abeta 17-42 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis. Brain 125, 2036-2043.
77. Pereira C, Ferreiro E, Cardoso SM, de Oliveira CR (2004) Cell degeneration induced by amyloid-beta peptides: Implications for Alzheimer's disease. J Mol Neurosci 23, 97-104.
78. Bhaskar K, Miller M, Chludzinski A, Herrup K, Zagorski M, Lamb BT (2009) The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events. Mol Neurodegener 4, 14.
79. Fuentealba RA, Farias G, Scheu J, Bronfman M, Marzolo MP, Inestrosa NC (2004) Signal transduction during amyloid-beta-peptide neurotoxicity: Role in Alzheimer disease. Brain Res Brain Res Rev 47, 275-289.
80. Mattson MP, Tomaselli KJ, Rydel RE (1993) Calciumdestablizing and neurodegenerative effect of aggregated beta-amyloid peptide are attenuated by basic FGF. Brain Res 621, 35-49.
81. Hartmann H, Eckert A, Müller WE (1994) Disturbances of the neuronal calcium homeostasis in the aging nervous system. Life Sci 55, 2011-2018.
82. Müller WE, Kirsch C, Eckert GP (2001) Membranedisordering effects of beta-amyloid peptides. Biochem Soc Trans 29, 617-623.
83. Verdier Y, Zarandi M, Penke B (2004) Amyloid betapeptide interactions with neuronal and glial cell plasma membrane: Binding sites and implications for Alzheimer's disease. J Pept Sci 10, 229-248.
84. Giulian D, Haverkamp LJ, Yu JH, Karshin W, Tom D, Li J, Kirkpatrick J, Kuo YM, Roher AE (1996) Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J Neurosci 16, 6021-6037.
85. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112.
86. Ferreira ST, Vieira MN, De Felice FG (2007) Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 59, 332-345.
87. Glabe CG, Kayed R (2006) Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66, S74-S78.
88. Bharadwaj PR, Dubey AK, Masters CL, Martins RN, Macreadie IG (2009) Abeta aggregation and possible implications in Alzheimer's disease pathogenesis. J Cell Mol Med 13, 412-421.
89. May PC, Boggs LN, Fuson KS (1993) Neurotoxicity of human amylin in rat primary hippocampal cultures: Similarity to Alzheimer's disease amyloid-beta neurotoxicity. J Neurochem 61, 2330-2333.
90. Lim YA, Rhein V, Baysang G, Meier F, Poljak A, Raftery MJ, Guilhaus M, Ittner LM, Eckert A, Götz J (2010) Abeta and human amylin share a common toxicity pathway via mitochondrial dysfunction. Proteomics 10, 1621-1633.
91. Jarosz-Griffiths HH, Noble E, Rushworth JV, Hooper NM (2016) Amyloid-β receptors: The good, the bad, and the prion protein. J Biol Chem 291, 3174-3183.
92. Roher AE, Esh CL, Kokjohn TA, Castaño EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo YM, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sabbagh MN (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 5, 18-29.
93. Miklossy J, Qing H, Radenovic A, Kis A, Vileno B, Làszló F, Miller L, Martins RN, Waeber G, Mooser V, Bosman F, Khalili K, Darbinian N, McGeer PL (2010) Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging 31, 1503-1515.
94. Kulstad JJ, Green PS, Cook DG, Watson GS, Reger MA, Baker LD, Plymate SR, Asthana S, Rhoads K, Mehta PD, Craft S (2006) Differential modulation of plasma betaamyloid by insulin in patients with Alzheimer disease. Neurology 66, 1506-1510.
95. Takeda S, Sato N, Uchio-Yamada K, Yu H, Moriguchi A, Rakugi H, Morishita R (2012) Oral glucose loading modulates plasma β-amyloid level in Alzheimer's disease patients: Potential diagnostic method for Alzheimer's disease. Dement Geriatr Cogn Disord 34, 25-30.
96. Yang Y, Wu Y, Zhang S, Song W (2013) High glucose promotes Aβ production by inhibiting APP degradation. PLoS One 8, e69824.
97. Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H (2001) Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 21, 2561-2570.
98. Zhang Y, Zhou B, Deng B, Zhang F, Wu J, Wang Y, Le Y, Zhai Q (2013) Amyloid-β induces hepatic insulin resistance in vivo via JAK2. Diabetes 62, 1159-1166.
99. Arrieta-Cruz I, Gutiérrez-Juárez R (2016) The role of insulin resistance and glucose metabolism dysregulation in the development of Alzheimer's disease. Rev Invest Clin 68, 53-58.
100. Clarke JR, Lyra E, Silva NM, Figueiredo CP, Frozza RL, Ledo JH, Beckman D, Katashima CK, Razolli D, Carvalho BM, Frazão R, Silveira MA, Ribeiro FC, Bomfim TR, Neves FS, Klein WL, Medeiros R, LaFerla FM, Carvalheira JB, Saad MJ, Munoz DP, Velloso LA, Ferreira ST, De Felice FG (2015) Alzheimer-associated A oligomers impact the central nervous system to induce peripheral metabolic deregulation. EMBO Mol Med 7, 190-210.
101. Standaert DG, Lee VM, Greenberg BD, Lowery DE, Trojanowski JQ (1991) Molecular features of hypothalamic plaques in Alzheimer's disease. AmJ Pathol 139, 681-691.
102. Meakin PJ, Harper AJ, Hamilton DL, Gallagher J, McNeilly AD, Burgess LA, Vaanholt LM, Bannon KA, Latcham J, Hussain I, Speakman JR, Howlett DR, Ashford ML (2012) Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice. Biochem J 441, 285-296.
103. Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R (2002) Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 22, RC221.
104. Figueroa DJ, Shi XP, Gardell SJ, Austin CP (2001) Abetapp secretases are co-expressed with Abetapp in the pancreatic islets. J Alzheimers Dis 3, 393-396.
105. Hu R, Zhang M, Chen H, Jiang B, Zheng J (2015) Crossseeding interaction between β-amyloid and human islet amyloid polypeptide. ACS Chem Neurosci 6, 1759-1768.
106. Gu Y, Oyama F, Ihara Y (1996) Tau is widely expressed in rat tissues. J Neurochem 67, 1235-1244.
107. Maj M, Gartner W, Ilhan A, Neziri D, Attems J, Wagner L (2010) Expression of TAUin insulin-secreting cells and its interaction with the calcium-binding protein secretagogin. J Endocrinol 205, 25-36.
108. Maj M, Hoermann G, Rasul S, Base W, Wagner L, Attems J (2016) The microtubule-associated protein tau and its relevance for pancreatic beta cells. J Diabetes Res 2006, 1964634.
109. Balczon R, Overstreet KA, Zinkowski RP, Haynes A, Appel M (1992) The identification, purification, and characterization of a pancreatic beta-cell form of the microtubule adenosine triphosphatase kinesin. Endocrinology 131, 331-336.
110. Meng YX, Wilson GW, Avery MC, Varden CH, Balczon R (1997) Suppression of the expression of a pancreatic beta-cell form of the kinesin heavy chain by antisense oligonucleotides inhibits insulin secretion from primary cultures of mouse beta-cells. Endocrinology 138, 1979-1987.
111. Suprenant KA, Dentler WL (1982) Association between endocrine pancreatic secretory granules and in-vitroassembled microtubules is dependent upon microtubuleassociated proteins. J Cell Biol 93, 164-174.
112. Malaisse WJ, Van Obberghen E, Devis G, Somers G, Ravazzola M (1974) Dynamics of insulin release and microtubular-microfilamentous system.V.Amodel for the phasic release of insulin. Eur J Clin Invest 4, 313-318.
113. Zhu X, Hu R, Brissova M, Stein RW, Powers AC, Gu G, Kaverina I (2015) Microtubules negatively regulate insulin secretion in pancreatic β cells. Dev Cell 34, 656-668.
114. Alvim RO, Cheuhen MR, Machado SR, Sousa AG, Santos PC (2015) General aspects of muscle glucose uptake. An Acad Bras Cienc 87, 351-368.
115. Olson AL, Trumbly AR, Gibson GV (2001) Insulinmediated GLUT4 translocation is dependent on the microtubule network. J Biol Chem 276, 10706-10714.
116. Fletcher LM, Welsh GI, Oatey PB, Tavaré JM (2000) Role for the microtubule cytoskeleton in GLUT4 vesicle trafficking and in the regulation of insulin-stimulated glucose uptake. Biochem J 352, 267-276.
117. Liu LZ, Cheung SC, Lan LL, Ho SK, Chan JC, Tong PC (2013) Microtubule network is required for insulininduced signal transduction and actin remodeling. Mol Cell Endocrinol 365, 64-74.
118. Hong M, Lee VM (1997) Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 272, 19547-19553.
119. Emoto M, Langille SE, Czech MP (2001) A role for kinesin in insulin-stimulated GLUT4 glucose transporter translocation in 3T3-L1 adipocytes. J Biol Chem 276, 10677-10682.
120. Kimura R, MacTavish D, Yang J, WestawayD, Jhamandas JH (2012) Beta amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor. J Neurosci 32, 17401-17406.
121. Christopoulos G, Paxinos G, Huang XF, Beaumont K, Toga AW, Sexton PM (1995) Comparative distribution of receptors for amylin and the related peptides calcitonin gene related peptide and calcitonin in rat and monkey brain. Can J Physiol Pharmacol 73, 1037-1041.
122. Götz J, Lim YA, Eckert A (2013) Lessons from two prevalent amyloidoses-what amylin and A have in common. Front Aging Neurosci 5, 38.
123. Grunberger G (2013) Novel therapies for the management of type 2 diabetes mellitus: Part 1. pramlintide and bromocriptine-QR. J Diabetes 5, 110-117.
124. Zhu H, Wang X, Wallack M, Li H, Carreras I, Dedeoglu A, Hur JY, Zheng H, Li H, Fine R, Mwamburi M, Sun X, Kowall N, Stern RA, Qiu WQ (2015) Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease. Mol Psychiatry 20, 252-262.
125. Adler BL, Yarchoan M, Hwang HM, Louneva N, Blair JA, Palm R, Smith MA, Lee HG, Arnold SE, Casadesus G (2014) Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. Neurobiol Aging 35, 793-801.
126. Toledo JB, Shaw LM, Trojanowski JQ (2013) Plasma amyloid beta measurements-a desired but elusive Alzheimer's disease biomarker. Alzheimers Res Ther 5, 8.